Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031597 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von James Gutmans und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland. Hauptthemen laut MEDLINE: Ampulla of Vater, Common Bile Duct Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ampullary carcinoma (AC) is a rare gastrointestinal malignancy with dual intestinal and pancreatobiliary differentiation, complicating diagnosis, staging, and treatment. This review synthesizes current epidemiology, pathology, and multi-omic data to outline a pragmatic care pathway: lineage-first at presentation, mutation-fast at progression. Histology remains the primary classifier: the intestinal subtype generally aligns with colorectal regimens, whereas pancreatobiliary and mixed subtypes favor pancreaticobiliary therapy. In selected fit patients, modified FOLFIRINOX may address mixed phenotypes. Next-generation sequencing adds precision by identifying therapeutically relevant alterations, including ERBB2/HER2 amplifications, MSI-high/dMMR, BRAF V600E, and rare NTRK or RET fusions, while KRAS mutations are enriched in pancreatobiliary tumors. We recommend early application of a rapid-core panel (KRAS/BRAF, MSI/dMMR, ERBB2/HER2, RNA-based fusions) to capture high-impact targets, followed by comprehensive profiling at first progression. Liquid biopsy, plasma circulating tumor DNA (ctDNA), or bile-derived DNA may complement tissue and help identify the dominant lineage. Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland.
- Clinique Générale Beaulieu, 1206 Geneva, Switzerland.
ORCID-Profile: James Gutmans, Hiba Mechahougui
Zitieren
APA
Gutmans, J., Friedlaender, A., & Mechahougui, H. (2026). Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031597
Vancouver
Gutmans J, Friedlaender A, Mechahougui H. Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031597
BibTeX
@article{Gutmans2026,
author = {Gutmans, James and Friedlaender, Alex and Mechahougui, Hiba},
title = {Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031597}
}
EUVIMED